Upon receptor binding, lanreotide exerts its antitumour effects through multiple mechanisms: (i) inhibition of growth-promoting hormones and peptides, leading to reduced tumour proliferation; (ii) induction of cell cycle arrest; and (iii) suppression of growth hormone (GH) secretion in the pituitary [98,99]. Here, GH1 is linked to neoplasm.